Publications

2022 April 12 AACR Conference (poster 3599)

Interleukin-10 and transforming growth factor-b do not suppress tumor killing activity of PBMC-derived SUPLEXA cells

View Conclusion & Download
2021 November 15 SITC conference (poster 164)

Potent Tumor Organoid Infiltration and Killing by PBMC Derived Effector Cells

View Conclusion & Download
2019 Nov 6-10 Society for Immunotherapy of Cancer (SITC) conference

Conversion of peripheral blood mononuclear cells into tumor-specific cytolytic cell populations using tumor cells engineered with multiple immunomodulatory factors

View Conclusion & Download
2021 Mar 24-25 Innate Killer Cell conference

A Differentiated and Broadly Applicable Autologous Whole Blood Derived Adoptive Cellular Therapy for Treating Cancer

View Conclusion & Download
2021 Mar 26-29 ISCT conference

Characterization of a Novel Autologous Pan-Cancer Cellular Immunotherapy

View Conclusion & Download
2021 Apr 9 AACR conference (poster 1772)

Development of PBMC derived tumor effector cells with potent pan-cancer cytolytic activity for autologous cellular immunotherapy

View Conclusion & Download
2021 April 9 AACR conference (poster 1531)

A novel approach for autologous pan-cancer cellular immunotherapy reveals dramatic expansion of αβ and γδ TCR T cell clonotypes indicative of an antigen-driven response

View Conclusion & Download
2021 June 4-8 ASCO Conference (poster 7517)

Engineered immunostimulatory cells can convert PBMCs from chronic lymphocytic leukemia (CLL) patients into potent tumor killing immune cells.

View Conclusion & Download